An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).

Who May Qualify: - A patient will be eligible for inclusion in this study only if ALL of the following criteria apply: - diagnosed by tissue sample (biopsy-confirmed) cT2-T4a,N0-N+,M0 resectable esophageal squamous cell carcinoma. - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Patients approve and sign the willing to sign a consent form Who Should NOT Join This Trial: - Patients with active autoimmune conditions (where your immune system attacks your own body) or history of autoimmune conditions (where your immune system attacks your own body). - Patients who have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications. - Subjects with a history of symptomatic interstitial lung disease. - History of allergy to study drug components. - Women must not be pregnant or breast-feeding. - Men with female partners (WOCBP) that are not willing to use contraception. - Patient has received prior chemotherapy, radiotherapy, target therapy and immune therapy for this malignancy or for any other past malignancy. - medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events Always talk to your doctor about whether this trial is right for you.